Parcourir par sujet "human epidermal growth factor receptor 2 negative breast cancer"
Voici les éléments 1-3 de 3
-
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane
(2021)Purpose: Detection of CTCs represents a poor prognostic factor in patients with early and metastatic breast cancer (mBC) and treatment with everolimus–exemestane (E/E) is an established effective treatment in hormone ... -
Epithelial-to-mesenchymal transition heterogeneity of circulating tumor cells and their correlation with mdscs and tregs in HER2-negative metastatic breast cancer patients
(2021)Background: To investigate the correlation between circulating tumor cells (CTCs) bearing cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) phenotypes and the different immunosuppressive cells in peripheral blood ... -
Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: A pooled analysis of randomized controlled trias by the hellenic academy of oncology
(2019)Background: Adjuvant chemotherapy has an indisputable value for early breast cancer patients. Anthracycline and taxane-based regimens (TaxAC) have not been proven superior to taxane & cyclophosphamide (TC), a less toxic ...